Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Clinical Trials in Taiwan / NCT03624751
Active, not recruiting Observational

Follow up for Patients With Thyroid Cancer Planed for Radioiodine Scan or Treatment

NCT03624751 · tracked via the Priya Life Science Taiwan tracker
Sponsor
Taichung Veterans General Hospital
Phase
Observational
Started
2018-06-06
Last updated
2026-05-01

Condition(s) studied

Thyroid Cancer

Investigational drug(s) / intervention(s)

radioiodine

radioiodine: Patients with thyroid cancer need to choose between Thyrogen® injection and Eltroxin® withdrawal before radioiodine therapy or scan.

Study summary

The prevalence of thyroid cancer has increased in recent decades. Patients with thyroid cancer need to choose between Thyrogen® injection and Eltroxin® withdrawal before radioiodine therapy or scan. This is a prospective, observational study, aiming to observe the difference of metabolic profiles between patients choose Thyrogen® injection and Eltroxin® withdrawal.

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: 1. Patients with diagnosis of thyroid cancer。 2. Patients who need radioiodine therapy or scan。 Exclusion Criteria: 1. Patients cannot cooperate with blood test.。 2. Patients cannot cooperate with radioiodine therapy。

Primary outcome measure(s)

  • Zung's Self-reported depression scale — 1 month
    Depression symtpoms

Trial sites (1)

FacilityCityRegionStatus
Division of Endocrinology and Metabolism in Taichung Veterans General Hospital Taichung Taiwan

More Taichung Veterans General Hospital trials in Taiwan

Taiwan Severe Asthma Biologic Registry Recruiting
Lyophilized Platelet-Rich Plasma Lysate vs Dextrose Prolotherapy for Partial Rotator Cuff Tears Active, not recruiting
3D Modeling for Detecting Locally Advanced Rectal Cancer With Positive Circumferential Resection Margin Starting soon
Optimized Diagnosis and Precision Medicine of MODY Recruiting
Perioperative NALIRIFOX (liposomal Irinotecan in Combination with Fluorouracil, Leucovorin, and Oxaliplatin) in Resectable Pancreatic Adenocarcinoma: Randomized Phase II Trial Recruiting

Other trials for the same condition

A Taiwanese Oncogenetic Panel and Integrated Clinical Data Registry Study for Advanced Thyroid Cancer Patients (TOPICS-THYROID) Active, not recruiting
Correlation Between Various Urinary Exosomal Protein Biomarkers and Pathological Manifestation in Thyroid Follicular Neoplasm: Early and Pre-operative Diagnosis of Follicular Thyroid Cancer Active, not recruiting
Urinary Exosomal Biomarkers of Thyroglobulin and Galectin-3 for Prognosis and Follow-up in Patients of Thyroid Cancer Active, not recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT03624751 on ClinicalTrials.gov ↗ ← All trials in Taiwan